Hong‐Hong Yan

Potential Predictive Value of <i>TP53</i> and <i>KRAS</i> Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Zhong‐Yi Dong, Wen‐Zhao Zhong, Xu‐Chao Zhang et al. · Clinical Cancer Research · 2016 · 971 citations

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · The Lancet Oncology · 2017 · 520 citations

Medicine, Pathology, Gefitinib Versus Vinorelbine +8

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy

Y.S. Li, Bo Jiang, Jin‐Ji Yang et al. · Annals of Oncology · 2018 · 328 citations · Full text

Cancer Research, Unique Genetic Profiles, Oncology +11

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

Yang-Si Li, Ben‐Yuan Jiang, Jin‐Ji Yang et al. · Journal of Thoracic Oncology · 2016 · 311 citations · Full text

Leptomeningeal Metastases, Medicine, Pathology +3

Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial

Wen‐Zhao Zhong, Qun Wang, Weimin Mao et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text